课题基金 / 基金详情

项目摘要

项目成果

ANDREW P EVAN的其他基金

相似基金

相关文献

中文摘要
翻译
在我们之前的资助期间,我们表明,临床剂量的冲击波应用于一个肾脏的下极肾盏,在F2会导致可预见的损害,减少两个肾脏的肾脏血流量,并产生与危险因素相关的肾脏反应。这些风险因素包括千伏、肾脏大小、施加的冲击波数量、先前存在的肾脏炎症或疾病,以及在同一治疗过程中对同一肾脏的两极施加的冲击波。由于较新的第三代碎石机在碎石方面的效率较低,似乎比Dornier HM3碎石机更容易造成不良影响,因此此次更新应用将扩大我们现有的重点,包括对新的和新兴的碎石机的研究。这类研究的目标是开发新的治疗策略和技术,有可能提高所有碎石机的疗效和安全性。 在目标1中,项目1将确定SWL诱导的肾血管收缩的时程和机制。为此,我们将与项目3进行互动。目标2将专注于SWL的几个新的风险因素。这些因素包括可能会恶化或减少被冲击波破坏的肾组织发生出血的倾向的条件(例如,高或低血压)和SWS的给药参数(例如,脉冲重复频率)。为此,我们将与项目2进行互动。目的3将空化与血管损伤相关联,以确定空化是否是细胞损伤的主要机制。我们将与项目3和4互动,以实现这一目标。目的4研究低能量冲击波预处理保护肾脏免受高能冲击波所致血管损伤的机制。可以想象,大多数由临床剂量的冲击波引起的细胞损伤可以通过我们的预处理方案来预防,从而减少患者的任何长期肾脏并发症,特别是那些接受多种治疗的患者。为此,我们将与项目2进行互动。AIM 5将评估第三代碎石机(例如,具有紧密焦点区域和高入射压力的紧凑型Delta碎石机)和SWL(双头碎石机,DiREx“Duet”)中的一项新兴技术,以评估它们导致肾损伤和损害肾功能的可能性。我们将与项目2和3进行互动,以实现这一目标。 所有这些拟议的研究都旨在了解SWS的不利影响,并在SWL不良反应报告不断增加的情况下,提高SWL对所有结石患者的安全性。
英文摘要
During our previous funding period we showed that a clinical dose of shock waves applied to the lower pole calyx of one kidney induces a predictable lesion at F2, reduces renal blood flow in both kidneys, and produces a renal response the severity of which is related to risk factors. These risk factors include kilovoltage, kidney size, number of shock waves administered, pre-existing renal inflammation or disease, and shock waves applied to both poles of the same kidney during the same treatment session. Since the newer 3rd-generation lithotripters are known to be less effective at breaking stones and appear to be more prone to cause adverse effects than the Dornier HM3 lithotripter, this renewal application will expand our existing focus to include studies of the new and emerging lithotripters. The goal of such studies is to develop new treatment strategies and technologies with the potential to improve the efficacy and safety of all lithotripters. In Aim 1, Project 1 will determine the time-course and mechanism of SWL-induced renal vasoconstriction. We will interact with Project 3 for this Aim. Aim 2 will focus on several new risk factors for SWL. These factors include conditions that might be expected to worsen or lessen the tendency for bleeding to occur in renal tissue damaged by shock waves (e.g., high or low blood pressure) and parameters for administration of SWs (e.g., pulse repetition rate). We will interact with Project 2 for this Aim. Aim 3 will correlate cavitation with the vascular lesions to determine if cavitation is the primary mechanism of cell injury. We will interact with Projects 3 & 4 for this Aim. Aim 4 will characterize the mechanism whereby pretreatment with low-energy shock waves protects the kidney form vascular damage induced by high-energy shock waves. It is conceivable that most of the cellular damage induced by a clinical dose of shock wave can be prevented by our pretreatment protocol, thereby, reducing any long-term renal complications for the patient, especially those receiving multiple treatments. We will interact with Project 2 for this Aim. Aim 5 will assess a 3rd generation lithotripter (e.g., Compact Delta that has a tight-focal-zone and high-incident-pressure) and an emerging technology in SWL (twin head lithotripter, the Direx "Duet") for their potential to cause renal trauma and impair renal function. We will interact with Projects 2 and 3 for this Aim. All of these proposed studies aim at understanding the adverse effects of SWs and advancing the safety of SWL for all stone patients at a time when reports of adverse effects in SWL are on the rise.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
PATHOPHYSIOLOGY AND HISTOPATHOLOGY OF NEPHROLITHIASIS
  • 批准号:
    8231181
  • 项目类别:
  • 资助金额:
    $34.75万
  • 财政年份:
    2011
  • 负责人:
    ANDREW P EVAN
  • 依托单位:
PATHOLOGY CORE
  • 批准号:
    8231135
  • 项目类别:
  • 资助金额:
    $27.31万
  • 财政年份:
    2011
  • 负责人:
    ANDREW P EVAN
  • 依托单位:
IKSI: 2nd International Urolithiasis Research Symposium
  • 批准号:
    7540831
  • 项目类别:
  • 资助金额:
    $1.0万
  • 财政年份:
    2008
  • 负责人:
    ANDREW P EVAN
  • 依托单位:
HISTOPATHOLOGIC DETERMINANTS OF HUMAN NEPHROLITHIASIS
  • 批准号:
    7490030
  • 项目类别:
  • 资助金额:
    $4.68万
  • 财政年份:
    2007
  • 负责人:
    ANDREW P EVAN
  • 依托单位:
国内基金
海外基金
基于ADK/Adenosine调控DNA甲基化探讨“利湿化瘀通络”法对2型糖尿病肾病足细胞裂孔膜损伤的干预机制研究
  • 批准号:
    82074359
  • 项目类别:
    面上项目
  • 资助金额:
    55.0万元
  • 批准年份:
    2020
  • 负责人:
    安晓飞
  • 依托单位:
细胞外腺苷(Adenosine)作为干细胞旁分泌因子的生物学鉴定和功能分析
Adenosine诱导A1/A2AR稳态失衡启动慢性低灌注白质炎性损伤及其机制